Exhibit 99.1

 

 

Vycor Medical Reports Financial Results for the three and nine months ended September 30th, 2017

 

BOCA RATON, FL (November 13, 2017) – Vycor Medical, Inc. (Vycor) (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, reported financial results for the three and nine months ended September 30, 2017.

 

Vycor’s revenues for the nine months ended September 30, 2017 were $1,115,000 compared to $1,105,000 for the same period in 2016. Cash Operating Loss1 was $316,000, as compared to $506,000 for the same period in 2016, a reduction of 38%, and Operating Loss was $949,000 compared to $1,122,000, a reduction of 15%.

 

Highlights

 

 

Vycor sales grew by 17% for the three months to September 30, 2017 compared to 2016. Vycor has been in the process, during 2017, of modifying its existing VBAS product range to make it easier to integrate with Imaging Guided Systems. The Company experienced manufacturing delays in connection with this re-engineering during the first half of 2017 and as a result was unable to fulfill shipments of certain models, particularly for some large international orders. These delays were resolved and most back orders were filled during the third quarter, however this resulted in sales year to date being marginally lower (1%) compared to 2016.

     
  A clinical study on Vycor’s VBAS was published by surgeons at the Hofstra Northwell School of Medicine during the period, demonstrating a novel technique combining VBAS, neuro-navigation and microsurgery. The VBAS was fundamental to this study, which concluded that the combination improves safety and patient outcomes and has broad value for the resection of a variety of deep brain lesions. In addition, a congress poster presented by surgeons at Weill Cornell was published in the Journal of Neurosurgery; this showcased VBAS as facilitating surgery to anterior artery aneurisms and lesions of the anterior third ventricles. A total of 18 papers have now been published or presented demonstrating the clinical benefits of VBAS, 12 in the last two years.
     
  During the period the US patent office issued/allowed 4 patents, all directed to the integration of neuro-navigation systems with Vycor’s VBAS retractor system. These patents complement and strengthen Vycor’s existing patent portfolio, particularly in relation to its ongoing focus to more fully integrate its VBAS product range with neuro-navigation systems. Management believes that providing surgeons with the ability to both optically and electronically visualize the location of the VBAS retractor will further drive the product’s adoption.

 

 

1 Operating Loss before Depreciation, Amortization and non-cash Stock Compensation. See Reconciliation table

 

 
 

 

  Vycor has, since 2012, been taking action against a potential Chinese competitor breaching its Chinese patent. The Chinese Patent Re-examination Board issued a decision in 2014 invalidating the competitor’s patent and this decision was upheld on appeal by the Patent Review Board. The time for final appeal by the competitor has now passed. The successful conclusion of this case confirms the priority of Vycor’s China patent to competitors and also makes clear that the Company will, as a general rule, take all necessary action to protect its patent portfolio to address any material violation thereof. VBAS now has 21 granted/issued and 10 pending patents for VBAS technologies, while NovaVision has 45 granted/issued and 1 pending patents for its technologies.
     
  NovaVision sales grew by 16% for the nine months to September 30, 2017 compared to 2016. NovaVision currently has approximately 250 patients undergoing its therapies in the US and internationally. Patient compliance is also strong, with 75% of patients who have started since the introduction of the Internet model completing the full 6 months of VRT, and over 30% extending for additional therapy beyond 6 months.

 

Management Commentary

 

“The Vycor division revenues in the second quarter were somewhat disappointing, however this was largely due to unavoidable delays created in manufacturing of our enhanced VBAS product. We are pleased to say these delays were resolved, resulting in a return to growth in the third quarter. We are optimistic the enhanced VBAS will be well accepted by the neurosurgical community” said Peter Zachariou, CEO of Vycor Medical. “NovaVision’s patient volumes have now outstripped the impact of our lowered pricing to patients, so we are continuing to see growth in revenues. We continue to decrease our Cash Operating Loss2 despite our investment in manufacturing and new products, which reduced to $316,000 for the nine months compared to $506,000 for the same period in 2016.”

 

Third Quarter 2017 Financial Results

 

Revenue totaled $379,000 in the quarter ended September 30, 2017, as compared to $326,000 for the prior year, an increase of 17%. Vycor Medical’s revenue in the period increased by 17% to $327,000 and NovaVision recorded revenues of $52,000 for the period, an increase of 14% over the same period in 2016.

 

Operating Expenses in the quarter ended September 30, 2017 totaled $619,000 as compared to $603,000 in the prior year period, and Cash Operating Expenses3 were $405,000 as compared to $466,000, a reduction of 13%, despite the costs of our investment program. Operating Loss was $296,000, compared to $315,000 for the same period in 2016, a decrease of 6%, and Cash Operating Loss2 was $81,000, as compared to $178,000 a decrease of 54%.

 

Net Loss for the quarter ended September 30, 2017 was $428,000 as compared to $332,000 in 2016.

 

 

2 Operating Loss before Depreciation, Amortization and non-cash Stock Compensation. See Reconciliation table

3 Operating Expenses before Depreciation, Amortization and non-cash Stock Compensation. See Reconciliation table

 

 
 

 

First Nine Months 2017 Financial Results

 

Revenue totaled $1,115,000 in the nine months ended September 30, 2017, as compared to $1,105,000 for the prior year, an increase of 1%. Vycor Medical’s revenue in the period decreased by $13,000 to $949,000, with US sales growing by 6%, offset by reduced international sales. International sales tend to be irregular as international distributors follow a pattern of placing large stocking orders. In addition, Vycor has been in the process, during 2017, of modifying its existing VBAS product suite to make it easier to integrate with Imaging Guided Systems. The Company experienced manufacturing delays in connection with this re-engineering during the first half of 2017 and as a result was unable to fulfill shipments of certain models, particularly for some large international orders. These delays were resolved and most back orders were filled during the third quarter.

 

NovaVision recorded revenues of $166,000 for the nine months ended September 30, 2017, an increase of 16% over the same period in 2016.

 

Operating Expenses in the nine months ended September 30, 2017 totaled $1,922,000 as compared to $2,074,000 in the prior year period, and Cash Operating Expenses[4] were $1,288,000 as compared to $1,459,000, a reduction of 12%. Operating Loss was $949,000, compared to $1,122,000 for the same period in 2016, a decrease of 15%, and Cash Operating Loss[5] was $316,000, as compared to $506,000, a decrease of 38%.

 

Net Loss for the nine months ended September 30, 2017 was $1,102,000 as compared to $1,165,000 in 2016.

 

About Vycor Medical, Inc.

 

Vycor Medical (OTCQB: VYCO) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions. The company has a portfolio of FDA cleared or registered medical solutions that are changing and improving lives every day. The company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

 

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

 

Non-GAAP Measures

 

We make reference to non-GAAP financial information in this press release together with a reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures. Specifically, we have provided non-GAAP Cash Operating Expenses and non-GAAP Cash Operating Loss measures that exclude Depreciation, Amortization and non-cash Stock Compensation.

 

 

4 Operating Expenses before Depreciation, Amortization and non-cash Stock Compensation. See Reconciliation table

5 Operating Loss before Depreciation, Amortization and non-cash Stock Compensation. See Reconciliation table

 

 
 

 

We believe that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of our ongoing operating results and trends, compared with historical results. This presentation is also consistent with the measures management uses to measure the performance of ongoing operating results against prior periods and against our internally developed targets. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures in this press release.

 

Safe Harbor Statement

 

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

 

 
 

 

VYCOR MEDICAL, INC.
Consolidated Statements of Comprehensive Loss

 

   For the three months ended September 30,   For the nine months ended September 30, 
   2017   2016   2017   2016 
                 
Revenue  $379,073   $325,777   $1,115,155   $1,105,269 
Cost of Revenues Sold   55,332    37,516    142,753    152,843 
Gross Profit   323,741    288,261    972,402    952,426 
                     
Operating expenses:                    
Research and development   -    4,153    -    4,153 
Depreciation and Amortization   72,734    63,797    211,369    193,391 
General and administrative   546,615    535,535    1,710,244    1,876,382 
Total Operating expenses   619,349    603,485    1,921,613    2,073,926 
Operating loss   (295,608)   (315,224)   (949,211)   (1,121,500)
                     
Other income (expense)                    
Interest expense: Other   (11,360)   (12,348)   (32,217)   (36,535)
Interest expense: Related Party   -    (4,663)   (679)   (5,910)
Warrant issuance expense   (120,788)   -    (120,788)   - 
Gain (loss) on foreign currency exchange   (646)   337    986    (877)
Total Other Income (expense)   (132,794)   (16,674)   (152,698)   (43,322)
                     
Loss Before Credit for Income Taxes   (428,402)   (331,898)   (1,101,909)   (1,164,822)
Credit for income taxes   -    -    -    - 
Net Loss   (428,402)   (331,898)   (1,101,909)   (1,164,822)
Preferred stock dividends   (162,185)   (91,409)   (324,370)   (179,727)
Net Loss available to common shareholders   (590,587)   (423,307)   (1,426,279)   (1,344,549)
Comprehensive Loss                    
Net Loss   (428,402)   (331,898)   (1,101,909)   (1,164,822)
Foreign Currency Translation Adjustment   1,728    1,504    4,687    4,426 
Comprehensive Loss   (426,674)   (330,394)   (1,097,222)   (1,160,396)
                     
Net Loss Per Share                    
Basic and diluted  ($0.03)  ($0.04)  ($0.08)  ($0.12)
                     
Weighted Average Number of Shares Outstanding – Basic and Diluted   19,715,156    11,094,763    17,895,269    11,012,689 

 

 
 

 

Reconciliation of Non GAAP Cash Operating Expenses and Non GAAP Cash Operating Loss Before Depreciation, Amortization and Other Non-Cash Items

 

   For the three months ended September 30,   For the nine months ended September 30, 
   2017   2016   2017   2016 
                 
GAAP Operating Expenses   (619,349)   (603,485)   (1,921,613)   (2,073,926)
                     
Non-cash depreciation   29,675    23,841    82,193    70,041 
Non-cash amortization of intangible assets   43,059    38,956    129,176    122,350 
Non-cash stock-based compensation   141,937    74,721    422,305    422,671 
                     
Non GAAP Cash Operating Expenses   (404,678)   (465,967)   (1,287,939)   (1,458,864)
                     
GAAP Operating Loss   (295,608)   (315,224)   (949,211)   (1,121,500)
                     
Non-cash depreciation   29,675    23,841    82,193    70,041 
Non-cash amortization of intangible assets   43,059    38,956    129,176    122,350 
Non-cash stock-based compensation   141,937    74,721    422,305    422,671 
                     
Non GAAP Operating loss Before                    
Depreciation and Amortization   (80,937)   (177,706)   (315,537)   (506,438)

 

Vycor Medical, Inc Contacts:

 

951 Broken Sound Parkway

Suite 320

Boca Raton, FL. 33487

(561) 558-2020

 

info@vycormedical.com

 

 
 

View differences made from one to another to evaluate Vycor Medical Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Vycor Medical Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account